J&J's (JNJ) Experimental TB Drug Receives Unanimous FDA Panel Backing

November 28, 2012 5:19 PM EST Send to a Friend
Johnson & Johnson (NYSE: JNJ) got some good news late Wednesday after an FDA panel said it would back its experimental tuberculosis drug, bedaquiline.

The drug targets adenosine triphosphate synthase, which is an enzyme that TB needs to generate energy.

The FDA panel voted 10 to 0 on the matter, commenting that clinical trial data supported efficacy of bedaquiline in adults, taken in combination with standard treatments.

Johnson & Johnson plans to commence a phase 3 in the fourth quarter. Shares are flat in late trading.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment